

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Trade application : SITI ARIJA MAD ARIF, ET AL.  
Application No. : 10/789,312  
Filed : February 27, 2004  
Confirmation No. : 9773  
For : ALLERGENIC LATEX PROTEIN  
Attorney's Docket : SIRIM-007XX

TC Art Unit: 1653

\*\*\*\*\*  
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 28, 2004

By James F. Thompson  
James F. Thompson  
Registration No. 36,699  
Attorney for Applicant(s)

\*\*\*\*\*

PRIORITY CLAIM UNDER RULE 55

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The benefit of the filing date in Malaysia of a patent application corresponding to the above-identified application is hereby claimed under Rule 55 and 35 U.S.C. 119 in accordance with the Paris Convention for the Protection of Industrial Property. This benefit is claimed based upon a corresponding Malaysian patent application bearing serial no. PI 2003 0734 filed February 28, 2003; a certified copy of which is attached hereto.

Respectfully submitted,

SITI ARIJA MAD ARIF, ET AL.

By James F. Thompson  
James F. Thompson  
Registration No. 36,699  
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,  
GAGNEBIN & LEOVICI LLP  
Ten Post Office Square  
Boston, Massachusetts 02109  
Telephone: (617) 542-2290  
Telecopier: (617) 451-0313


Date: April 28, 2004

JFT/mc/302063-1  
Enclosure



**Perbadanan Harta Intelek Malaysia**  
**Intellectual Property Corporation of Malaysia**

Aras 27, 30 dan 32, Menara Dayabumi, Jalan Sultan Hishamuddin, 50623 Kuala Lumpur, Malaysia.  
Tel: 603-2274 2100 Fax: 603-2274 1332 Website: [www.mipc.gov.my](http://www.mipc.gov.my)



WEINGARTEN, SCHURGIN, GAGNEBIN & LEOVICI LLP  
TEN POST OFFICE SQUARE  
BOSTON, MASSACHUSETTS 02109 *SIRIM-007XX*  
*10/789,312*

**DR. MARGERET CHAI SOOK YIN**  
SIRIM BERHAD  
1 Persiaran Dato' Menteri,  
Seksyen 2, P.O.Box 7035,  
40000 Shah Alam  
Selangor, **MALAYSIA**

**PATENT APPLICATION NO: PI 20030734**

This is to certify that annexed hereto is a true copy from the records of the Registry of Trade Marks and Patents, Malaysia of the application as originally filed which is identified therein.



By authority of the  
REGISTRAR OF PATENTS

**ROZANAH MISKAN**  
(CERTIFYING OFFICER)  
13 April 2004  
Tel: 03-22748970  
[rozanah@mipc.gov.my](mailto:rozanah@mipc.gov.my)



Perbadanan Harta Intelek Malaysia  
Intellectual Property Corporation of Malaysia

Perbadanan Harta Intelek Malaysia  
(Intellectual Property Corporation of Malaysia)  
Aras 32, Menara Dayabumi,  
Jalan Sultan Hishamuddin,  
50623 Kuala Lumpur

Telefon: 03-2274 8671  
Fax : 03-2274 1332  
<http://www.mipc.gov.my>


---

## CERTIFICATE OF FILING

APPLICANT : MALAYSIAN RUBBER BOARD  
APPLICATION NO : PI 20030734  
REQUEST RECEIVED ON : 28/02/2003  
FILING DATE : 28/02/2003  
AGENT'S/APPLICANT'S FILE REF. : ISD 426/13/1 (EPD/2002-10/37)

Please find attached, a copy of the Request Form relating to the above application, with the filing date and application number marked thereon in accordance with Regulation 25(1).

Date : 11/03/2003

  
\_\_\_\_\_  
(ROZILEE BIN ASID)  
for Registrar of Patents

To : DR. MARGARET CHAI SOOK YIN  
SIRIM BERHAD,  
1, PERSIARAN DATO'MENTERI,  
SEKSYEN 2,  
40000- SHAH ALAM  
MALAYSIA

**Patents Form No. 1**  
**PATENTS ACT 1983**

**REQUEST FOR GRANT OF PATENT**  
**[Regulations 7(1))**

To : The Registrar of Patents  
Patent Registration Office  
Kuala Lumpur,  
Malaysia

For Official Use  
APPLICATION NO. P1 20030734  
APPLICATION RECEIVED NO. : 28-02-2003

Fee received on: 28-02-2003

Amount : RM 1270  
\*Cheque/Postal Order/Money Order/Draft/Cash

CASH

Date of mailing :

Please submit this Form in duplicate  
Together with the prescribed fee.

Applicant's Reference :

ISD 426/13/1 (EPD/2002-10/37)

**THE APPLICANT(S) REQUEST(S) THE GRANT OF A PATENT IN RESPECT OF THE  
FOLLOWING PARTICULARS**

I. TITLE OF INVENTION : A PROTEIN

II. APPLICANT(s) the data concerning each applicant must appear in this box or, if the space is insufficient, in the space below)

Name : MALAYSIAN RUBBER BOARD

I.C./Passport No. : \_\_\_\_\_

Address : 18 th Floor, Bangunan Getah Asli (Menara), 148, Jalan Ampang,  
50450 Kuala Lumpur, Malaysia.

Address for service in Malaysia : Intellectual Property Services Section, SIRIM Berhad, 1,  
Persiaran Dato' Menteri, Section 2, 40000 Shah Alam,  
Selangor Darul Ehsan, Malaysia.

Nationality : A Statutory Body incorporated under the Malaysian Rubber Board  
(Incorporation ) Act 1996 of Malaysia.

\* Permanent residence or principal place of business :

As above.

Telephone Number  
(if any)

03-92062000

Fax Number  
(if any)

03-21634492

Additional Information (if any)

200 30734

III. INVENTOR

Applicant is the inventor

Yes

☐

No

☒

If the applicant is not the inventor :

Name of Inventors: 1) SITI ARIJA MAD ARIF 2) CHEW NYU PING 3) YEANG HOONG YEET

Address of Inventors: All from: Biotechnology and Strategic Research Unit,  
Malaysian Rubber Board, RRIM Research Station,  
47000 Sungai Buloh, Selangor, Malaysia.

A statement justifying the applicant's right to the patent accompanies this Form :

Yes

☒

No

☐

Additional Information (if any)

IV. AGENT OR REPRESENTATIVE

Applicant has appointed a patent agent in accompanying  
Form No. 17

Yes

☒

No

☐

Agent's Registration No. : PA/2000/0099

Applicants have appointed  
to be their common representative

V. DIVISIONAL APPLICATION

This application is a divisional application

☐

The benefit of the  
filing date


priority date

☐

of the initial application is claimed in as much as the subject-matter of the present application is  
contained in the initial application identified below :

Initial Application No. :

Date of filing of initial application :



200 30 7 3 4

VI. DISCLOSURE TO BE DISREGARDED FOR PRIOR ART PURPOSES

Additional information is contained in supplemental box :

(a) Disclosure was due to acts of applicant or his predecessor in title

☐

Date of disclosure: \_\_\_\_\_

(b) Disclosure was due to abuse of rights of applicant or his predecessor in title

☐

Date of disclosure: \_\_\_\_\_

A statement specifying in more detail the facts concerning the disclosure accompanies this Form

Yes

☐

No

☐

Additional Information (If any)

VII. PRIORITY CLAIM (if any)

The priority of an earlier application is claimed as follows :

Country (if the earlier application is a regional or international application, indicate the office with which it is filed) :

Filing Date : \_\_\_\_\_

Application No. : \_\_\_\_\_

Symbol of the International Patent Classification :

If not yet allocated, please tick

☐

The priority of more than one earlier application is claimed:

Yes

☐

No

☐

The certified copy of the earlier application(s) accompanies this Form:

Yes

☐


No

☐

If No, it will be furnished by

Additional Information (if any)

200 30734



### VIII. CHECK LIST


A. This application contains the following :

1. request	_____	Sheets
2. description	_____	20 Sheets
3. claim	_____	9 Sheets
4. abstract	_____	1 Sheets
5. drawings	_____	7 Sheets
Total	_____	37 Sheets

B. This Form, as filed, is accompanied by the items checked below :

(a) signed Form No. 17 – to be followed soon (original PF 17)	<input checked="" type="checkbox"/>
(b) declaration that inventor does not wish to be named in the patent	<input type="checkbox"/>
(c) statement justifying applicant's right to the patent	<input checked="" type="checkbox"/>
(e) priority document (certified copy of earlier application)	<input type="checkbox"/>
(f) cash, cheque, money order, banker's draft or postal order for the payment of application fee – Cash RM 270.00	<input checked="" type="checkbox"/>
(g) other documents (specify)	<input type="checkbox"/>

IX. SIGNATURE



DR. MARGARET CHAI SOOK YIN

\*\* (Applicant/Agent)

28/2/2003

(Date)

If Agent, indicate Agent's Registration No. : PA/2000/0099

For Official Use

1. Date application received :
2. Date of receipt of correction, later filed papers or drawings completing the application :

\* Delete whichever does not apply

\*\* Type name under signature and delete whichever does not apply

200 3047 3 4



## A PROTEIN

### 1. Technical Field of The Invention

The present invention relates in general to a protein.

### 5 2. Background of The invention

By the late 1980s and into the 90s, reports began to be received with increasing frequency in Europe and America of allergic reactions occurring among users of surgical and examination gloves made of latex and among spina bifida patients. The significant increase in the number of reports of latex allergy in the last decade has also been attributed to increased usage of latex gloves in healthcare in tandem with the rising cases of AIDS. Sensitisation to latex among healthcare workers is clearly work-related, the main cause being latex gloves, or specifically, the allergenic protein in latex gloves. Nevertheless, numerous cross-sensitivities between latex protein allergens and various food and pollen allergens are known. It is therefore not improbable that many latex-allergic patients may have been initially sensitised not only by proteins from latex products, but also by proteins from other sources.

There are hundreds of proteins found in natural rubber latex. Of these, only a small handful is allergenic (able to induce allergy). There has been much interest in identifying the proteins in *Hevea* latex responsible for latex allergy and considerable effort is expended on isolating and purifying the allergenic proteins

from *Hevea* latex or latex products. Other than from the academic standpoint, elucidation of the major allergens in latex would enable antibodies to be developed against these proteins. Availability of the antibodies would facilitate the development of latex immunoassays, both for laboratory and commercial use. There are two main types of latex immunoassays

1. *Immunoassays for latex allergy diagnosis*

These diagnostics are used to determine if someone is allergic or sensitized to latex. The assays can either be of the *in vitro* format (usually a serological test) or of the *in vivo* format (skin prick tests). These assays are used in research and in healthcare.

2. *Immunoassays for the quantitation of latex allergens in manufactured products*

These quantitative assays determine the amount of allergenic proteins present in latex products. They are used for testing latex products such as latex gloves to determine the content of extractable latex allergens. Such immunoassays would be very valuable in latex product manufacture, particularly in the aspects of standardisation and quality control and quality assurance. The prospective customers for such immunoassays would be latex product manufacturers and regulatory agencies charged with the responsibility of ensuring product specification compliance.

Identification of the major latex allergens serves another useful function in healthcare. Purified latex allergens can be used in immunotherapy to de-sensitise latex allergic patients. When successfully undertaken, the patient no longer develops an allergic reaction to latex. This is especially important where the patient works in an environment (e.g. in healthcare) where latex products are ubiquitous.

Today, the International Union of Immunological Societies (IUIS) recognises ten latex allergens, Hev b 1 to Hev b 10. (There are other latex proteins under consideration by the IUIS.) Although there is effort being made to look for significant latex protein allergens, many researchers believe that most of the major latex protein allergens have been accounted for.

In 1995, Dr Donald Beezhold in his paper presented at *Int Conf on Latex Protein Allergy: The Latest Position* announced a new latex allergen that had partial protein homology to patatin, the major storage protein of potatoes. This 43 kDa protein is later assigned the WHO/IUIS name Hev b 7. When a recombinant version of Hev b 7 became available, it is found to be reactive with IgE from latex allergic patients. However, the proportion of patients that are sensitised to recombinant Hev b 7 is much lower than expected. Western blots that showed an active protein band around 43 kDa protein is much more commonly encountered than could be explained by IgE binding to Hev b 7. Hence, the recombinant Hev b 7 could not account for the very frequent occurrence of latex

sensitivity to a protein of about 43 kDa. It is, therefore, possible that another unknown latex allergen of around 43 kDa existed. The search for this new and unknown protein has culminated in the present invention. This protein is allergenic in nature in that contact with allergenic latex protein (ALP) can induce an allergic reaction in persons sensitized to this protein.

### 3. Summary of the Invention

According to the most general aspect of the present invention, there is provided a protein originating from latex that can induce an allergic reaction in persons sensitized to the protein.

Preferably, the protein or its molecular variant characterized in that the protein has the following properties:

- a) has a molecular weight of about 42,000 Dalton;
- b) has an isoelectric point of about 4.7;
- c) binds with IgE of patients sensitized to the protein; and
- d) contains the amino acid sequence as in Figure 2 or minor variations of these amino acid sequence that do not result in the allergenic properties of the protein being substantially altered.

The second aspect of the present invention provides for a process for obtaining a protein or its molecular variant where the process comprises the

following steps:

- a) centrifuging the latex for obtaining the bottom fraction;
- 5 b) freeze-thawing the bottom fraction for obtaining the latex B-serum; and
- c) isolating and purifying the protein from the B-serum obtained in (b).

10 The third aspect of the present invention provides for a peptide that is derived from the protein where the peptide has similar allergenic properties as the protein.

Further, the present invention provides for a DNA sequence encoding the protein or a portion of the protein where the DNA sequence is as Figure 1 or minor  
15 variations of this sequence.

Also, the present invention provides a method for the production of a protein or its molecular variants in recombinant form by inserting the DNA encoding the protein or a variant of the protein into an  
20 appropriate vector and inducing the vector to express recombinant protein or in recombinant form of the said variant of the protein, whereby in this case, the amino acid sequence of the above translated DNA sequence are as in Figure 2.

#### 25 4. Brief Description of the Figures

Figure 1 shows the DNA sequence of the full length cDNA clone encoding the ALP.

Figure 2 shows the amino acid sequence of the ALP derived from the translation of the cDNA clone encoding the ALP.

5 Figure 3 shows the matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) spectrum of the allergenic latex protein, ALP.

10 Figure 4 shows a Western blot of ALP after separation of the protein by SDS-polyacrylamide gel electrophoresis. The protein is stained with Coomassie Blue to show the presence and electrophoretic migration of ALP (lane 2). Binding of human IgE of patients sensitised to ALP on the Western blot (lane 3), polyclonal antibodies developed against ALP (lane 4), and a monoclonal antibody developed against ALP (lane 15 5).

Figure 5 shows a Western blot of ALP after separation of the protein by SDS-polyacrylamide gel electrophoresis. The protein is stained with Coomassie Blue to show the presence and electrophoretic migration of ALP (lane 2). A reaction specific for the presence of carbohydrates is carried out to demonstrate glycosylation of ALP (lane 3).

25 Figure 6 shows a Western blot of the recombinant MBP-ALP fusion protein after separation by SDS-PAGE. The protein is stained with Coomassie Blue to show the electrophoretic migration of the recombinant ALP fusion protein (lane 3). Binding of recombinant ALP to

monoclonal (Lane 4) and polyclonal antibodies (lane 5) developed against native ALP is also shown.

#### **Detailed description of the invention**

5 The present invention relates to a protein isolated from the B-serum of centrifuged latex obtained by tapping the rubber tree, *Hevea brasiliensis*. The following description details how the protein can be isolated, purified and characterized, and how it might be used in cloning the cDNA encoding the protein, how  
10 recombinant versions of the protein can be obtained, how antibodies might be developed from the protein and how the protein can be used in immunoassay and immunotherapy.

#### **Example 1. Protein isolation and purification**

15 Fresh latex from *Hevea brasiliensis* trees (clone RRIM 600) is collected into chilled containers. The latex is centrifuged at 19,000 r.p.m. (43,000 g) on a Sorvall RC 5C high-speed centrifuge for 1 h at 4-7°C to separate it into three main fractions: the top  
20 fraction which is the rubber cream, the heavy bottom fraction and the C-serum located in between. Latex B-serum is prepared based on the method of Hsia (1958) *Trans Instn Rubb Ind*. The latex bottom fraction from centrifuged latex is washed by re-suspension in 0.4M  
25 mannitol and recovered by centrifugation. The washed bottom fraction is then subjected to repeated freezing and thawing to rupture the lutoids that are its main constituents. The lutoidic fluid, the B-serum, is recovered as the supernatant after re-centrifugation.

B-serum is dialysed overnight against 0.3mM sodium borate and 0.016 M boric acid pH 7 in the cold room. This is followed with filtration through Whatman No. 1 filter paper. Ten ml of the filtered B-serum is loaded onto carboxymethyl cellulose CM32 (Whatman) column (20 cm x 1.5 cm) equilibrated with 0.09 M sodium borate and 0.016 M boric acid, pH 8.6. Proteins are eluted with a gradient of 150 ml of 0.09M sodium borate and 0.016 M boric acid, pH 8.6 against 150 ml of 0.9M sodium borate and 0.16 M boric acid, pH 8.6. Two ml fractions are collected at a rate of 2.6 min/fraction. The unretarded materials (i.e. fractions 3 to 11) are loaded into a DE 52 (Whatman) column (12 cm x 1.5 cm) equilibrated with 0.1 M Tris-HCl, pH 8. The protein is eluted with a gradient of 0 - 0.5 M NaCl in the same buffer. Fractions containing proteins of about 43 kDa, as determined by SDS-polyacrylamide gel electrophoresis, are tested for immunoglobulin IgE binding with serum latex-allergic patients. The fractions containing ALP are identified and pooled. The approximate molecular weight of ALP determined by comparing the migration of ALP with that of various calibration markers is 42 kDa (Figure 4 lane 2).

**Example 2. Molecular weight and isoelectric point determination and amino acid sequencing**

The accurate molecular weight of the allergenic latex protein, ALP, determined by mass spectrometry is 42975. The matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) spectrum of the protein sample is shown in Figure 3.



The isoelectric point (pI) of ALP is determined by isoelectric focusing (IEF). The migration of the protein on the IEF gel is measured and compared with protein calibration standards of known pI. The pI of  
5 ALP is estimated to be 4.7.

The protein is found to be blocked at the N-terminal. *In situ* digestion by trypsin resulted in several fragments. Partial amino acid sequences are obtained for three of these fragments.

10 Sequence 1: YLDVQYSQFR

Sequence 2: YSLFSEPEK

Sequence 3: LPTTIIPAHGGFSSR

where the letters of the alphabet are accepted abbreviations for individual amino acids.

15 Sequence 1 is derived from a peptide of 1319 Da. The amino acid sequence data obtained by mass spectrometry is compared against the protein sequence database of the National Centre for Biotechnology Information (NCBI), USA, using the BLAST algorithm. The search  
20 revealed that the amino acid sequences had partial homology with the "early nodule-specific protein" of *Glycine max*.

Sequence 2 is derived from a peptide of 1100 Da. The sequence showed partial homology with "early nodule-specific protein" of *Medicago truncatula*.  
25

Sequence 3 is derived from a peptide of 1556 Da. The sequence showed partial homology with "early nodule-specific protein" of *Glycine max*.

**Example 3. Determination of glycosylation of ALP**

5 To demonstrate that a carbohydrate is bound to the ALP protein (rendering ALP a 'glycosylated protein' or glycoprotein), purified proteins are separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 15% gels and transferred electrophoretically to a  
10 nitrocellulose membrane to obtain a Western Blot. The membrane is washed with phosphate buffered saline (PBS) and then immersed into 10 mM sodium periodate/EDTA with agitation in the dark for 20 min. Following this, the membrane is washed three times  
15 with PBS for 10 minutes each cycle. The membrane is next transferred to a solution made up of biotin-hydrazide in sodium acetate/EDTA and agitation is carried out for 60 min. After washing three cycles with Tris-buffered saline (TBS), the membrane is  
20 blocked and then washed over another three cycles with TBS. The membrane is then immersed in strepavidin-alkaline phosphatase for 60 min. After another three cycles of washing with TBS, the membrane is immersed in a solution of 5-bromo-4-chloro-3-indolyl  
25 phosphate/nitro blue tetrazolium (BCIP/NBT) substrate. The appearance of the coloured alkaline phosphatase reaction product indicated the presence of the carbohydrate component of the glycoprotein (Figure 5).

**Example 4. Production of antibodies against ALP**

Both polyclonal antibodies and monoclonal antibodies are successfully developed against ALP.

*Polyclonal antibodies against ALP*

5 A pure preparation of ALP (approximately 0.5 ml of 0.5 mg ALP/ml) in phosphate buffered saline (PBS) is mixed with an equal volume of complete Freund's adjuvant and this antigen mixture is injected subcutaneously into the back of rabbits. Seven booster dose of the same antigen formulation, but with incomplete Freund's  
10 adjuvant, are administered at two week intervals. Blood is drawn from the rabbits to obtain the anti-serum that contained polyclonal antibodies against ALP.

15 To demonstrate polyclonal antibody binding to ALP, a Western blot of the protein on to nitrocellulose membrane is prepared as in Example 3. The nitrocellulose membrane is blocked with 5% non-fat milk in PBS and then incubated for 90 min with anti-  
20 ALP polyclonal antibodies (diluted 1:800 in PBS-milk) as the primary antibody. After three cycles of washing with PBS-milk, the nitrocellulose membrane is incubated for 1 h with the secondary antibody, anti-rabbit IgG conjugated to alkaline phosphatase. After  
25 a further three cycles of washing with PBS-milk, the nitrocellulose membrane is incubated for 10 min in Tris buffered saline (TBS) before being immersed in 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) substrate to generate the  
30 coloured alkaline phosphatase reaction product. The

binding of polyclonal antibodies to ALP on a Western blot of the protein after separation of the protein by SDS-polyacrylamide gel electrophoresis is shown in Figure 5 (lane 4).

5      *Monoclonal antibodies against ALP*

Spleen cells from a Balb/c mouse immunized with latex C-serum are fused with mouse myeloma cells following protocols previously described by Kohler and Milstein (12,13). The resulting hybridoma cells are screened  
10      for antibodies specific to C-serum proteins. Selected hybridomas are re-cloned twice and monoclonal antibodies secreted are used either in unpurified form in hybridoma cell supernatants or as preparations purified by affinity chromatography.

15              To demonstrate monoclonal antibody binding to ALP, a Western blot of the protein on to nitrocellulose membrane and processed as for the polyclonal antibody, except that monoclonal antibody against ALP is used as the primary antibody, while  
20      anti-mouse IgG conjugated to alkaline phosphatase is used as the secondary antibody. The binding of monoclonal antibodies to ALP on a Western blot of the protein after separation of the protein by SDS-polyacrylamide gel electrophoresis is shown in Figure 4  
25      (lane 5).

*Recombinant monoclonal antibodies against ALP*

An anticipated variation of the conventional monoclonal antibody is the recombinant antibody whereby the antibody can be generated using a specific

segment of DNA that encodes the amino acid sequence of the antibody or a functional fragment of the antibody such as a single chain variable fragment. There are several approaches to the development of recombinant antibodies, of which an example is outlined here. Antibody gene libraries are first constructed, for example, by PCR-amplification from B-lymphocyte cDNA. To screen these libraries, antibodies are displayed on the surface of microorganisms containing the antibody's gene (phage display). They are challenged with the antigen protein to identify specific clones producing an antibody that bind to this protein. Once the organism bearing the antibody gene is identified, specific clones can then be amplified and used to produce the antibody fragment in *E. coli* or other suitable organism.

**Example 5. Demonstration of protein allergenicity**

A Western blot of the purified protein is incubated with blood serum from latex allergic patients to determine if IgE (the immunoglobulin that mediates the allergic reaction) bound to the protein. Binding of IgE to the protein indicated that the protein is allergenic.

To detect protein-IgE binding in Western blots, a similar procedure as in Example 2 is followed, except that the nitrocellulose membrane is incubated overnight with serum pooled from several latex-allergic patients (diluted 1:5.25 in PBS-milk and 0.05% sodium azide) as the primary antibody. Anti-human IgE conjugated to alkaline phosphatase served as

<

the secondary antibody. The binding of human IgE to ALP on a Western blot of the protein after separation of the protein by SDS-polyacrylamide gel electrophoresis is shown in Figure 4 (lane 3).

5     **Example 6.     Preparation and cloning of the cDNA encoding ALP**

The complementary DNA (cDNA) encoding the amino acid sequence of ALP can be cloned and multiplied in a host such as a micro-organism. The micro-organism can be  
10     selected from the group consisting of bacteria, yeast, and viruses. Higher plant cells can also be used as vectors. The ALP protein, in recombinant form, can then be synthesised in the same host or in an alternative host. The following is a description of  
15     the method used to clone the cDNA of ALP. Standard methods are used in the preparation and purification of DNA, mini- and maxipreps, DNA purification, restriction endonuclease digestions, agarose gel electrophoresis, ligations, transformations and poly(A)<sup>+</sup> mRNA isolation  
20     by oligo(dT) cellulose column chromatography.

*Preparation of latex mRNA*

Latex is collected by tapping the *Hevea brasiliensis* tree. Before the tree is tapped, it is fitted with a sterilised drainage spout. Immediately upon tapping,  
25     the incision and spout are washed with about 20 ml of 2x RNA extraction buffer (0.1 mol Tris-HCl, 0.3 mol LiCl, 0.01 mol EDTA, 10% SDS, pH 9.5). The latex is then washed down with 100 ml of RNA extraction buffer to a total collected volume of 200 ml in a sterile  
30     conical flask. In the laboratory, the latex is mixed

well and centrifuged in polyallomer tubes at 112,700 g for 30 minutes at 15° C. The aqueous phase is gently decanted into sterile centrifuge tubes and subsequent processing of the aqueous phase to isolate total RNA is performed according to the method of Prescott and Martin (1987) *Plant Mol Biol Rep*.

#### *Synthesis of ALP cDNA*

First strand cDNA synthesis is prepared by reverse transcribing 1 microgram of total latex RNA in 20 µl volume using the GeneRacer™ Kit (Invitrogen , USA) as per the vendor's instructions. Synthesis of cDNA is accomplished by PCR amplification.

The cDNA is amplified by PCR without prior purification. Each reaction is performed in a 50 µl volume containing 2 µl of the first strand reaction above, 12.5 µM of GeneRacer™ 3' Primer ( 5'-GCTGTCAACGATACGCTACGTAACG-3' where A,G,C and T are the abbreviations for the nucleotides bases adenine, guanine, cytosine and thymine respectively), 12.5 µM of specific primer, 0.2 mMol dATP, 0.2 mMol dTTP, 0.2 mMol dCTP, 0.2 mMol dGTP, pH 7.5 , 1 unit of Taq High Fidelity (Roche Diagnostics GmbH) , 10 mM Tris-Hcl, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, pH 8.3, and overlaid with 50 µl of mineral oil. The PCR reaction took place in a thermocycler following the manufacturer's instructions. A second round of PCR is performed as previously but using 5 µl of the first round PCR as the template. 20 µl of the PCR amplification product is used for

analysis on a 1.0 % agarose gel stained with ethidium bromide.

*Cloning of ALP cDNA.*

The PCR product (about 1.5 Kb, in size ) is ligated  
 5 into the TOPO<sup>®</sup> vector (Invitrogen , USA) as per the  
 vendor's instructions. The ligate (2 µl) is used for  
 the transformation of One Shot<sup>®</sup> TOP10 Chemically  
 Competent *Escherichia coli* (Invitrogen , USA) to  
 ampicillin resistance. After incubating overnight at  
 10 37°C in agar medium containing ampicillin (100 µg/ml),  
 transformants were picked by Xgal (80 µg/ml)/IPTG (3  
 mmol/L) colour selection. The picked clones are  
 screened by miniprep assay using the Wizard<sup>®</sup> SV  
 Minipreps DNA Purification System (Promega , USA) as  
 15 per the vendor's instructions. 1 ug of the selected  
 clones are then sent for nucleic acid sequencing.

The DNA sequences (1394 basepairs, Figure 1) are  
 translated into the amino acids that they encoded  
 (Figure 2). The amino acid sequence encompassed the  
 20 following segments:

- 1) ctaccaactactattatacctgctcatgggtggatttagt (at position  
 384 to 422) encodes the peptide LPTTIIPAHGGFS
- 2) taccttgatgtccaatattcgcaattccgg (at position 429 to  
 458) encodes the peptide YLDVQYSQFR
- 25 3) tattctttatttcagtgagccagaaaaa (at position 897 to 923)  
 encodes the peptide YSLFSEPEK



where a,g,c and t are the abbreviations for the nucleotides bases adenine, guanine, cytosine and thymine respectively. As noted earlier, these three protein domains had been independently identified by mass spectrometry. The applicants note that minor variations of the DNA sequence would not alter substantially the basic characteristics of the peptide that the DNA encodes.

**Example 7. Over-expression of recombinant ALP**

There are several commercial kits that can be used for the over-expression of the allergenic latex protein. In this example, the pMAL-c2 protein fusion and purification system (New England Biolabs, USA) is used to overexpress recombinant protein from its cloned cDNA. The procedures used for the induction of fusion protein overproduction, affinity chromatography purification, cleavage of fusion protein by factor Xa protease, and purification of the target protein by hydroxyapatite chromatography are according to the vendor's instructions. In this example, isopropyl thiogalactoside (IPTG) is used as an inducer for the expression system.

The ALP cDNA is subcloned into the vector pMAL-c2 in the same translational reading frame as the *malE* gene of the vector. The bacterial cells are grown overnight at 37°C on an LB indicator plate containing 100 µg/ml ampicillin, 10 µmol isopropyl thiogalactoside (IPTG) and 10 µg/ml Xgal. White colonies are picked and screened for the presence of the MBP fusion plasmid by miniprep assay. A positive

clone is then taken for the overproduction of the REF protein. IPTG-induced *E. coli* cells are disrupted by a freeze (-20° C)/thaw cycle (ambient temperature) and sonicating (Vibra Cell, Sonics & Materials Inc., USA) in ice-water bath with 15 seconds pulses for 3 minutes. The release of fusion protein eluted from the amylose column is monitored by assaying for protein. Whereas the amino acid sequence of the peptide is determined by the cDNA sequence in the expression vector, the applicants note that minor changes in the cDNA sequence would not alter substantially the basic characteristics of the recombinant protein. Figure 6 shows the expressed recombinant protein and its binding to antibodies that had been developed against its native (natural) counterpart purified from natural rubber latex.

#### **Example 8. Use of ALP in immunoassays**

Native or recombinant ALP or its molecular variant (a protein similar to ALP, but differing slightly, for example, in a few amino acids) can be used on its own, or in combination with an antibody developed against ALP or its molecular variant, in immunoassays. Molecular variants of ALP may occur naturally in latex or may exist as a result of laboratory manipulation. Such variants of ALP may differ only slightly from one another (e.g. by a few amino acids) and they have substantially similar basic functions or characteristics including allergenicity. Such immunoassays can be constructed in many different formats, but they basically rely on the immunological reaction between an antibody and its antigen. The

antibody in this instance can be an antibody against ALP or its molecular variant, or human IgE. Its antigen can be native or recombinant ALP or its molecular variant, or a peptide that embodies the epitope site of ALP or its molecular variant.

The immunoassay can be used for the diagnosis of for the diagnosis of allergy to ALP or allergy to latex in general. In a different format, the immunoassay can be used for the detection of ALP in latex or latex products.

**Example 9. Use of ALP in immunotherapy**

Immunotherapy is a preventive treatment for allergic reactions that is carried out by giving gradually increasing doses of the allergen to which the person is allergic. The incremental increases of the allergen cause the immune system to become less sensitive to the substance when the substance is encountered in the future. There are several treatment protocols for immunotherapy. As an example, immunotherapy with ALP can be carried out by injecting a purified sample of ALP into the skin of the arm. An injection may be given once a week for about 30 weeks, after which injections can be administered every two weeks. Eventually, injections can be given every four weeks. The duration of therapy may be three or four years, sometimes longer. In place of native ALP, immunotherapy may also be carried out with a suitable recombinant ALP or the molecular variant of ALP (a protein similar to ALP, but differing slightly, for example, in a few amino acids), or a peptide

representing a portion of ALP or its molecular variant.

5 From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usage and conditions.

1. A protein or its molecular variant that can induce an allergic reaction in persons sensitized to the protein.

- 5

5

10

15

20

25

30

30            3.    A protein or its molecular variant as claimed in  
                 claim 1 or 2 characterized in that the protein or  
                 its molecular variant has the following  
                 properties:  
                 a.    has a molecular weight of about 42,000  
35                   Dalton;  
                 b.    has an isoelectric point of about 4.7;

- c. binds with IgE of patients sensitized to the protein; and
- d. contains the amino acid sequence or portions thereof or minor variations of these amino acid sequence as shown below:

5

```

AGALTLGFCFHFMEFPETNNNPITLSFLLCMLSLAYASETCDFPAIFNF
----1----1----1----1----1----1----1----1----1----1 50

GDSNSDTGGKAAAFYPLNPPYGETFFHRSTGRYSDGRLIIDFIAESFNLP
----1----1----1----1----1----1----1----1----1----1 100

YLSPYLSSLGSNFKHGADFATAGSTIKLPTTIIPAHGGFSPFYLDVQYSQ
----1----1----1----1----1----1----1----1----1----1 150

FRQFIPRSQFIRETGGIFAELVPEEYFFEKALYTFDIGQNDLTEGFLNLT
----1----1----1----1----1----1----1----1----1----1 200

VEEVNATVPDLVNSFSANVKKIYDLGARTFWIHNTGPIGCLSFILTYFPW
----1----1----1----1----1----1----1----1----1----1 250

AEKDSAGCAKAYNEVAQHFNHKLKEIVAQLRKDLPLATFVHVDIYSVKYS
----1----1----1----1----1----1----1----1----1----1 300

LFSEPEKHGFEFPLITCCGYGGKYNFSVTAPCGDVTADDGTKIVVGSCA
----1----1----1----1----1----1----1----1----1----1 350

CPSVRVNWDGAHYTEAANEYFFDQISTGAFSDPPVPLNMACHKTESLRTL
----1----1----1----1----1----1----1----1----1----1 400

ASV*VI*KCFAESPLIK*GIIINEKPLIMLGFTWFLS**SICCIYNSCMK
----1----1----1----1----1----1----1----1----1----1 450

*FLVIKTCLSPVSL
----1----1----1 464

```

25

4. A process for obtaining a protein or its molecular variant according to any one of Claims 1 - 3 wherein the process comprises the following steps:

30

- a) centrifuging the latex for obtaining the bottom fraction;
- b) freeze-thawing the bottom fraction for obtaining the latex B-serum; and

c) isolating and purifying the protein from the B-serum obtained in step (b).

5. A process for obtaining a protein or its molecular variant as claimed in Claim 4 wherein the isolation and purification of the protein are carried out via a series of chromatographic separations.

6. A process for obtaining a protein or its molecular variant as claimed in claim 5 wherein the chromatographic separation is ion exchange chromatography and gel filtration.

7. A peptide that is derived from the protein as claimed in any one of claims 1 - 3 or prepared according to the process as claimed in any one of claims 4 - 6 wherein the peptide has similar allergenic properties as the protein as claimed in claims 1 - 3.

8. A DNA sequence encoding the protein or a portion of the protein as claimed in claim 1 wherein the DNA sequence or minor variations of this sequence is as shown below:

DNA: acgcgggggcgttaacacttggtttttgcttccacttcatggagttccctg 51  
 ---l---l---l---l---l---l---l---l---l---l---l---

25 DNA: aaaccaataacaaccctatcatcactctctctttcttattatgcatgcttt 102  
 ---l---l---l---l---l---l---l---l---l---l---l---

DNA: ccctagcttatgcttccgaaacctgtgattttccagcaatctttaacttcg 153  
 --l---l---l---l---l---l---l---l---l---l---l---

DNA: gcgactccaattccgataccggtggcaaggcagctgccttttatcctctta 204  
 -l---l---l---l---l---l---l---l---l---l---l---



35

5

15

20

25

30

35

	DNA: tgagtccatatcttagttccctgggaagcaacttcaaacatggtgcagatt	357
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: ttgccacagcaggatccaccattaaactaccaactactattatacctgctc	408
	--1---1---1---1---1---1---1---1---1---1---1---	
5	DNA: atggtggattttagtccattctaccttgatgtccaatattcgcaattccggc	459
	-1---1---1---1---1---1---1---1---1---1---1---	
	DNA: aattcatacccagatcacagtttatcagggaaactggaggcatatttgctg	510
	1---1---1---1---1---1---1---1---1---1---1---	
10	DNA: aattggtgcccagggaatattattttgagaaagctttatacacattcgata	561
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: ttggtcaaaatgatcttacagaaggattcttgaacttaactgtggaagaag	612
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: tgaatgcaactgtccctgatcttgtgaatagcttctcagcaaacgttaaga	663
	--1---1---1---1---1---1---1---1---1---1---1---	
15	DNA: aaatatacgatttgggagctagaacattttggattcacacacaggaccaa	714
	-1---1---1---1---1---1---1---1---1---1---1---	
	DNA: ttggttgtctttcattcattttaacgtattttccctgggcagaaaaggata	765
	1---1---1---1---1---1---1---1---1---1---1---	
20	DNA: gtgcaggctgtgcaaaagcttacaatgaagttgtcagcattttaatcaca	816
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: agttgaaggagatcgttgctcaactcaggaaggatttgcctttagctacat	867
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: tcgtccacgttgacatctattctgtcaagtattctttattcagtgagccag	918
	--1---1---1---1---1---1---1---1---1---1---1---	
25	DNA: aaaaacacggtttcgagtttccacttataacatgttgtggctacggaggaa	969
	-1---1---1---1---1---1---1---1---1---1---1---	
	DNA: agtacaatttttagtggttactgctccatgtggagatacagttacagcagacg	1020
	1---1---1---1---1---1---1---1---1---1---1---	
30	DNA: acggtaccaaataagttgtgggttcatgtgcttgcccttcagttcgagtaa	1071
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: attgggatggagctcactacactgaagctgccaatgaatattttttcgacc	1122
	---1---1---1---1---1---1---1---1---1---1---1---	
	DNA: agatttctacaggagccttctctgatccccctgttccattgaatatggcat	1173
	--1---1---1---1---1---1---1---1---1---1---1---	
35	DNA: gtcataaaaactgaatcattgaggacattagcctctgtataggttatatgaa	1224
	-1---1---1---1---1---1---1---1---1---1---1---	
	DNA: agtgctttgctgaaagcccgctaataaaaatgaggaataataataaatgaga	1275
	1---1---1---1---1---1---1---1---1---1---1---	


DNA: aaccattgattatggttaggattcacttggtttctatcataataatctatct 1326  
 ----1-----1-----1-----1-----1-----1-----1-----1-----1-

DNA: gttgtatatacaacagttgtatgaaatagtttcttgtaataaagacttgtc 1377  
 ---1-----1-----1-----1-----1-----1-----1-----1-----1--

5 DNA: tttctccggtttcccta 1394  
 --1-----1-----1-----

11. A method for the production of a protein or its molecular variant in recombinant form as claimed in claim 9 or 10 wherein the vector is a micro-organism, a plant or an animal.
- 10 12. A method for the production of a protein or its molecular variant in recombinant form as claimed in claim 11 wherein the micro-organism is a bacterium, a virus or a yeast.
- 15 13. A method for the production of a protein or its molecular variant in recombinant form as claimed in claim 12 wherein the bacterium is *Escherichia coli*.
- 20 14. A method for the production of a protein or its molecular variant in recombinant form as claimed in claim 9 wherein the inducer is preferably isopropyl thiogalactoside (IPTG) or any other suitable inducer.
- 25 15. A recombinant protein or its molecular variant in recombinant form produced according to the methods as claimed in any one of claims 9 - 14.

16. The use of native protein or its molecular variant as claimed in any one of claims 1 - 7 in immunoassay and immunotherapy.
17. The use of recombinant protein or its molecular variant in recombinant form as claimed in any one of claims 8 -15 in immunoassay and immunotherapy.
- 5



**ABSTRACT****A PROTEIN**

5       The present invention relates to a protein found  
in natural rubber that can induce an allergic reaction  
in persons who have been sensitised to it. The  
invention provides for the process of isolating and  
purifying the protein and describes the  
characteristics of the protein, including its  
molecular weight, isoelectric point, amino acid  
10       sequence and allergenicity. The invention also  
describes the isolation and cloning a the DNA that  
encodes the protein. The production of the  
recombinant version of the protein using a protein  
expression vector is described.

**Figure 1.** DNA sequences of the cDNA clone encoding the protein,ALP.

DNA: acgcggggcggttaacacttggtttttgcttccacttcatggagttccctg	51
----1----1----1----1----1----1----1----1----1----1--	
DNA: aaaccaataacaaccctatcatcactctctcttttcttattatgcatgcttt	102
---1----1----1----1----1----1----1----1----1----1--	
DNA: ccctagcttatgcttccgaaacctgtgattttccagcaatctttaacttcg	153
--1----1----1----1----1----1----1----1----1----1---	
DNA: gcgactccaattccgataccggtggcaaggcagctgccttttatcctctta	204
-1----1----1----1----1----1----1----1----1----1----	
DNA: accctccttatggagagactttctttcacaggctcgacaggaagggtactctg	255
1----1----1----1----1----1----1----1----1----1----	
DNA: atggaaggctcataatagattttatcgccgagagtttcaatctcccatatc	306
----1----1----1----1----1----1----1----1----1----1--	
DNA: tgagtccatatcttagttccctgggaagcaacttcaaacatgggtgcagatt	357
---1----1----1----1----1----1----1----1----1----1--	
DNA: ttgccacagcaggatccaccattaaactaccaactactattatacctgctc	408
--1----1----1----1----1----1----1----1----1----1---	
DNA: atggtggatttagtccattctaccttgatgtccaatattcgcaattccggc	459
-1----1----1----1----1----1----1----1----1----1----	
DNA: aattcatacccagatcacagtttatcagggaaactggaggcatatttgctg	510
1----1----1----1----1----1----1----1----1----1----	
DNA: aattggtgcccgaggaatattattttgagaaagctttatacacattcgata	561
----1----1----1----1----1----1----1----1----1----1--	
DNA: ttggtcaaaatgatcttacagaaggattcttgaacttaactgtggaagaag	612
---1----1----1----1----1----1----1----1----1----1--	
DNA: tgaatgcaactgtccctgatcttgtgaatagcttctcagcaaactgtaaga	663
--1----1----1----1----1----1----1----1----1----1---	
DNA: aaatatacgatttgggagctagaacattttggattcacaacacaggaccaa	714
-1----1----1----1----1----1----1----1----1----1----	
DNA: ttggttgctctttcattcattttaacgtattttccctgggcagaaaaggata	765
1----1----1----1----1----1----1----1----1----1----	
DNA: gtgcaggctgtgcaaaagcttacaatgaagttgctcagcattttaatcaca	816
----1----1----1----1----1----1----1----1----1----1--	
DNA: agttgaaggagatcgttgctcaactcaggaaggatttgccttttagctacat	867

```

---1---1---1---1---1---1---1---1---1---1---1---
DNA: tcgtccacggttgacatctattctgtcaagtattctttattcagtgagccag 918
--1---1---1---1---1---1---1---1---1---1---1---

DNA: aaaaacacggttttcgagtttccacttataacatggttggtggctacggaggaa 969
-1---1---1---1---1---1---1---1---1---1---1---

DNA: agtacaatttttagtgttactgctccatgtggagatacagttacagcagacg 1020
1---1---1---1---1---1---1---1---1---1---1---

DNA: acggtaccaaaatagttgtgggttcattgtgcttgcccttcagttcgagtaa 1071
---1---1---1---1---1---1---1---1---1---1---1---

DNA: attgggatggagctcactacactgaagctgccaatgaatattttttcgacc 1122
---1---1---1---1---1---1---1---1---1---1---1---

DNA: agatttctacaggagccttctctgatccccctgttcattgaatatggcat 1173
--1---1---1---1---1---1---1---1---1---1---1---

DNA: gtcataaaactgaatcattgaggacattagcctctgtataggttatatgaa 1224
-1---1---1---1---1---1---1---1---1---1---1---

DNA: agtgctttgctgaaagcccgctaataaaatgaggaataataataaatgaga 1275
1---1---1---1---1---1---1---1---1---1---1---

DNA: aaccattgattatgttaggattcacttggtttctatcataataatctatct 1326
---1---1---1---1---1---1---1---1---1---1---1---

DNA: gttgtatatacaacagttgtatgaaatagtttcttgtaataaagacttgtc 1377
---1---1---1---1---1---1---1---1---1---1---1---

DNA: tttctccggtttcccta 1394
--1---1---1---1---

```



Figure 2. Amino acid sequence derived from the translation of the cDNA clone of the ALP.

```

AGALTLGFCFHFMEFPETNNNPIITLSFLLCMLSLAYASETCDFPAIFNF
----1----1----1----1----1----1----1----1----1----1  50

GDSNSDTGGKAAAFYPLNPPYGETFFHRSTGRYSDGRLLIDFIAESFNLP
----1----1----1----1----1----1----1----1----1----1  100

YLSPYLSSLGSNFKHGADFATAGSTIKLPTTIIPAHGGFSPFYLDVQYSQ
----1----1----1----1----1----1----1----1----1----1  150

FRQFIPRSQFIRETG GIFAELVPEEYFFEKALYTFDIGQNDLTEGFLNLT
----1----1----1----1----1----1----1----1----1----1  200

VEEVNATVPDLVNSFSANVKKIYDLGARTFWIHNTGPIGCLSFILTYFPW
----1----1----1----1----1----1----1----1----1----1  250

AEKDSAGCAKAYNEVAQHFNHKLKEIVAQLRKDLPLATFVHVVDIYSVKYS
----1----1----1----1----1----1----1----1----1----1  300

LFSEPEKHGFEFPLITCCGYGGKYNFSVTAPCGDTVTADDGTKIVVGSCA
----1----1----1----1----1----1----1----1----1----1  350

CPSVRVNWDGAHYTEAANEYFFDQISTGAFSDPPVPLNMACHKTESLRTL
----1----1----1----1----1----1----1----1----1----1  400

ASV*VI*KCFAESPLIK*GIIINEKPLIMLGFTWFLS**SICCIYNSCMK
----1----1----1----1----1----1----1----1----1----1  450

*FLVIKTCLSPVSL
----1----1----1  464

```

Figure 3. Determination of the molecular weight of ALP by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) following liquid chromatography.




Figure 4. Western blot of ALP . Lane 1) molecular weight marker stained with Coomassie blue; 2) ALP stained with Coomassie blue; 3) binding of immunoglobulin IgE to the ALP, indicating that the protein is allergenic; 4) binding of polyclonal antibodies to the ALP; 5) binding of a monoclonal antibodies to the ALP.




Figure 5. Western blot of ALP and the detection of the presence of carbohydrate associated with the protein, indicating that the protein is glycosylated. Lane 1) molecular weight marker stained with Coomassie blue; 2) ALP stained with Coomassie blue; 3) positive reaction to the glycosylation test.




Figure 6. Western blot of the recombinant Maltose Binding Protein (MBP)-ALP fusion protein after separation by SDS-PAGE. Lane 1) molecular weight marker stained with Coomassie blue; 2) Maltose binding protein (MBP) stained with Coomassie blue; 3) Recombinant ALP protein stained with Coomassie Blue; 4) Binding of monoclonal antibody developed against native ALP and 5) Binding of polyclonal antibodies developed against native ALP.